Servier Deal Termination Fails To Dent MacroGenics’ Flotetuzumab Optimism
The French firm has handed back rights to MacroGenics’ lead DART candidate flotetuzumab. Undaunted, MacroGenics is forging ahead with clinical development including in combination use, while the market awaits a filing and license deal for its lead product margetuximab.
You may also be interested in...
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
The largest-ever rise in the number of active R&D companies, particularly in China, helped propel an unprecedented increase in the size of the biopharma pipeline in 2019. Meanwhile, the number of new active substances launched in their first market last year dropped as 2018’s superlative performance gave way to something more usual.
Kadmon’s treatment for graft-versus-host disease, belumosudil continues to perform well in its pivotal ROCKstar study, setting the stage for a US filing under the FDA’s pilot Real-Time Oncology Review program.